About PAION AG

Company Description

PAION AG is a publicly listed specialty pharmaceutical company with innovative drugs to be used in hospital-based sedation, anesthesia and critical care services. PAION’s lead compound is remimazolam, an intravenous, ultra-short-acting and controllable benzodiazepine sedative/anesthetic. PAION has started to launch remimazolam (Byfavo) in selected European markets. Remimazolam is partnered in multiple territories outside of Europe. Remimazolam is approved in the U.S., the EU/EEA/UK, China and South Korea for procedural sedation and in Japan and South Korea for general anesthesia.

In addition, PAION markets two intensive care products in selected European countries: Angiotensin II (GIAPREZA), a vasoconstrictor indicated for the treatment of refractory hypotension in adults with septic or other distributive shock, and eravacycline (XERAVA), a novel fluorocycline type of antibiotic indicated for the treatment of complicated intra-abdominal infections in adults.

Year founded

2000

Served area

Worldwide

Headcount

51

Headquarters

Martinstraße 10-12, 52062 Aachen – Germany

Publications

Shareholder information

Shares outstanding

71,336,992

IPO

Feb. 11, 2005

Designated Sponsor(s)

Oddo BHF Corporates & Markets AG

Stock exchange(s)

Frankfurt Stock Exchange

Contact

Newsletter

Subscribe to our newsletter and receive information about recent IPOs, news in the European capital market and more.